MedTrace Logo

Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer

NCT04180761 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-04-03

No results posted yet for this study

Summary

This study investigates the effect of a combined therapy with gastrectomy and HIPEC in localized advanced gastric cancer.

Conditions

  • Gastric Neoplasms

Interventions

DRUG

intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)

single dose application of hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-30
Primary Completion
2022-03-31
Completion
2022-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04180761 on ClinicalTrials.gov